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Some forms of triamcinolone may provide alternate options for local therapy of the
inner ear in addition to the steroids currently in use. We compared the perilymph
pharmacokinetics of triamcinolone-acetonide, triamcinolone, and dexamethasone, each
delivered as crystalline suspensions to guinea pigs. Triamcinolone-acetonide is a widely
used form of the drug with molecular properties that allow it to readily permeate
biological barriers. When applied intratympanically triamcinolone-acetonide entered
perilymph rapidly but was also found to be eliminated rapidly from perilymph. The
rapid rate of elimination severely limits the apical distribution of the drug when
applied locally, making it unsuitable for use in the ear. In contrast, triamcinolone,
rather than triamcinolone-acetonide, is a more polar form of the molecule, with higher
aqueous solubility but calculated to pass less-readily through biological boundaries.
Perilymph concentrations generated with intratympanic applications of triamcinolone
were comparable to those with triamcinolone-acetonide but elimination measurements
showed that triamcinolone was retained in perilymph longer than triamcinolone-
acetonide or dexamethasone. The slower elimination is projected to result in improved
distribution of triamcinolone toward the cochlear apex, potentially allowing higher drug
levels to reach the speech frequency regions of the human ear. These measurements
show that triamcinolone could constitute an attractive additional treatment option for
local therapy of auditory disorders.
Keywords: intratympanic therapy, Meniere’s disease, idiopathic sudden sensorineural hearing loss,
dexamethasone, triamcinolone, triamcinolone acetonide
INTRODUCTION
Treatment of the inner ear with a locally applied steroid has become a widely accepted therapy
for Meniere’s disease, idiopathic sudden sensorineural hearing loss and immune-related hearing
loss. The choice of which steroid and what concentration to use has largely been established
empirically based except for a limited few pioneering studies where drug kinetics (dexamethasone
and methylprednisolone) were compared in animals (Parnes et al., 1999) and in humans
(Bird et al., 2007, 2011). Currently, steroids that have been used for local inner ear therapy
Abbreviations: LSCC, lateral semi-circular canal; RW, round window; ST, scala tympani; SV, scala vestibuli.
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include dexamethasone-phosphate (Liebau et al., 2017);
dexamethasone (Lambert et al., 2016); methylprednisolone-
succinate (Rauch et al., 2011; Liebau et al., 2017); and
triamcinolone-acetonide (Jumaily et al., 2017; Dahm et al., 2019).
We recently reported that dexamethasone-phosphate, the
most common form of dexamethasone used for local treatment
of the ear, has properties that make it quite unsuitable for
local therapy of the ear (Salt et al., 2018). The polar phosphate
group that makes the drug more soluble also makes this
form of the drug substantially less permeable though the RW
membrane than native dexamethasone, limiting the amount
entering. Within the ear it is then metabolized to the active form,
dexamethasone, which is highly permeable through the blood-
labyrinth barrier and is rapidly lost from perilymph. The high rate
of dexamethasone elimination limits how far the drug spreads
apically along the ear (Plontke et al., 2008; Salt et al., 2018). As
a result, concentrations reaching the speech frequency regions of
the human are calculated to be low (Liebau et al., 2017). Large
gradients along the ear will persist even when higher doses of
dexamethasone-phosphate are given (Alexander et al., 2015).
A second problem exists when the steroid is applied to the
middle ear as a solution. For dexamethasone-phosphate, loss
from the middle ear occurs rapidly. Measurement of the solution
remaining in the RW niche of guinea pigs demonstrated a decline
in concentration with a half-time of approximately 28 min
(Salt et al., 2018). This rate occurred in anesthetized recumbent
animals which did not lose volume through the Eustachian tube.
The rate of loss is likely to be even higher in the conscious
animal in normal posture in which fluid in the middle ear is
cleared by the ciliated ventral epithelium to the Eustachian tube
(Thompson and Tucker, 2013). The residence time of drug in the
middle ear has a major influence on the perilymph concentration
of drug achieved (Salt and Plontke, 2005). A longer drug
residence time in the middle ear can be achieved by delivering
the drug as a suspension. Measurable perilymph concentrations
of dexamethasone were achieved for over 3 months after
intratympanic application of dexamethasone suspension (Wang
et al., 2009; Piu et al., 2011). Both triamcinolone-acetonide
and triamcinolone exhibit low aqueous solubility making them
suitable for delivery to the middle ear as a suspension.
We therefore evaluated the pharmacokinetics of different
formulations these two compounds in perilymph and compared
them with comparable measurements with dexamethasone which
were previously reported (Salt et al., 2012, 2018).
The ability of molecules to pass through biological barriers
such as the blood-brain barrier and the gut has been shown
to depend on their lipid solubility and polar properties (Egan
et al., 2000; Daina and Zoete, 2016). A plot of lipid solubility
(WLOGP) against the polar surface area (TPSA) shows that
molecules with properties within a specific range can pass certain
biological boundaries, as shown in Figure 1. The gut is permeable
to molecules within a specific range (gray ellipse) while the blood-
brain barrier is more restrictive, only permeable to molecules
within a more limited range (yellow ellipse) (Daina and Zoete,
2016). The degree to which inner ear barriers, specifically those
between the middle ear and perilymph and between perilymph
and blood, compare to these better-studied boundaries remains
FIGURE 1 | Molecular properties compared for common forms of
dexamethasone and triamcinolone. WLOGP is a calculated index of lipid
solubility for the drug and TPSA represents the surface area of the molecule
occupied by polar groups. Large, polar, hydrophilic molecules (lower right of
plot) typically have high aqueous solubility but do not readily pass through
membranous biological boundaries. In contrast, small, non-polar lipophilic
molecules (upper left of plot) pass more readily through biological boundaries
but have lower aqueous solubility. The yellow ellipse indicates the range of
properties for molecules that pass through the blood brain barrier and the
gray ellipse indicates the range of properties for molecules that pass into the
body through the gut (Daina and Zoete, 2016). Dexamethasone-phosphate is
larger and more polar than dexamethasone, giving it higher aqueous solubility
but limiting passage through biological boundaries. Triamcinolone-acetonide is
calculated to pass boundaries more readily than dexamethasone while
triamcinolone is calculated to pass less readily.
to be determined. Nevertheless, molecules with properties located
toward the lower right side of the plot (large, hydrophilic, and
polar) are expected to pass through membranous biological
boundaries less easily than molecules located toward upper left
side of the plot (small, lipophilic, and non-polar). The plot shows
the molecular properties calculated by SwissADME1 (Daina et al.,
2017) for triamcinolone-acetonide and triamcinolone, compared
to those of dexamethasone-phosphate and dexamethasone.
Triamcinolone-acetonide is more lipophilic than dexamethasone
while triamcinolone is more polar and less lipophilic.
MATERIALS AND METHODS
Animals
The study used 32 pigmented, NIH-strain guinea pigs weighing
400–600 g. Experiments were performed under protocol
20160053, approved by the Institutional Animal Care and Use
Committee of Washington University. Animal use followed
policies in accordance with the United States Department of
Agriculture and National Institutes of Health guidelines for the
handling and use of laboratory animals.
In non-recovery perilymph sampling experiments, animals
were first anesthetized with 100 mg/kg sodium thiobutabarbital
(Inactin, Sigma, St. Louis, MO, United States). A tracheal
cannula was inserted and the animal was maintained on 0.8
to 1.2% isoflurane in oxygen using a mechanical ventilator.
End-tidal CO2 level was maintained close to 5% by adjustment
1http://www.swissadme.ch
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of the tidal volume of the ventilator. Heart rate and oxygen
saturation were monitored throughout the experiment. Core
body temperature was maintained at 38◦C with a thermistor-
controlled heating blanket.
The ear was exposed by opening the lateral portion of
the auditory bulla. This gave access to the LSCC and to the
RW niche. Drug solutions were either applied to the RW
niche or injected into perilymph of the lateral SCC. In all
experiments, perilymph was sampled from the lateral SCC. In
some experiments as detailed below, triamcinolone-acetonide
or triamcinolone suspension was applied intratympanically as
a recovery procedure, followed by perilymph sampling 1 or
3 days afterward.
Drug Delivery: Application to the Round
Window Niche
In non-recovery experiments, the lateral bulla was opened and
suspensions of triamcinolone-acetonide or triamcinolone were
applied to the RW niche with a hand-held micropipetter. A 20 µL
volume was applied, sufficient to fill the entire niche and
stapes area of the guinea pig, with excess overflowing toward
the anterior bulla.
Drug formulations were:
(1) Triamcinolone-acetonide 40 mg/mL injectable crystalline
suspension (Kenalog-40: Bristol-Myers Squibb, Princeton,
NJ, United States). Kenalog-40 also contains 0.99% benzyl
alcohol as a preservative (in higher concentrations shown
to increase permeability of the RW membrane and stapes;
Li et al., 2018) and 0.04% polysorbate-80 (Tween-80), an
emulsifier. This formulation was applied to two animals. The
aqueous solubility of triamcinolone-acetonide is reported
to be 42 µg/mL (Drugbank)2. We measured aqueous
solubility by taking a 1:1 dilution of the supernatant over
the suspension after it had settled for at least 24 h. The
concentration in the supernatant, corrected for dilution, was
26.5 µg/mL; SD 1.7; n = 4.
(2) Triamcinolone-acetonide (Spectrum Chemicals, New
Brunswick, NJ, United States) 60 mg/mL crystalline suspension
in PBS with 17% Poloxamer 407 (Spectrum Chemicals). This
formulation was applied to five animals.
(3) Triamcinolone (Sigma, St. Louis, MO, United States)
40 mg/mL suspension in PBS with 17% Poloxamer 407. This
formulation was applied to 12 animals. Aqueous solubility
of triamcinolone is reported to be 80 µg/mL (PubChem)3.
The concentration of the supernatant over the suspension was
measured to be 81.05 µg/mL; SD 29.4; n = 4).
Drug Delivery: Intratympanic Injection
The procedure for intratympanic injection of drug suspension
in poloxamer gel is described elsewhere in detail (Salt et al.,
2011). The guinea pig was anesthetized with isoflurane (0.8–
1.2% in oxygen) and buprenorphine (0.05 mg/kg) given for
analgesia. The head of the animal was positioned against a
foam pad on a head-holder with its nose vertically upward, held
in position by a Velcro strap. A speculum was placed in the
2https://www.drugbank.ca/
3http://pubchem.ncbi.nlm.nih.gov
right ear, allowing the tympanic membrane to be visualized.
A hypodermic needle held in a manipulator was used to make
two perforations in the tympanic membrane, one anterior to the
umbo as a vent and a second posterior to the umbo for injection.
Drug injection through the latter perforation was performed
from a blunt-tipped 26G needle, bent 90 degrees and attached
to a syringe mounted on a syringe pump (Ultrapump; World
Precision Instruments, Sarasota, FL).
Perilymph was sampled from the LSCC either 1 or 3 days
after the application of the drug formulation. Triamcinolone-
acetonide suspension was applied in three animals followed by
perilymph sampling 1 day later. Triamcinolone suspension was
applied in 6 animals followed by perlilymph sampling 1 day
(n = 4) or 3 days (n = 2) later.
Drug Delivery: Injection Into the Lateral
Semi-Circular Canal
The rates of elimination of triamcinolone or triamcinolone-
acetonide from perilymph were measured by first loading the
perilymph with drug solution as detailed in Salt et al. (2012). At
varying times after application (zero, 1 or 2 h) perilymph was
sampled from the LSCC for analysis to establish how much drug
remained in perilymph. The injected solution consisted of the
supernatant over the suspension as described above, diluted 1:1
in a bicarbonate-buffered artificial perilymph. Triamcinolone-
acetonide solution was applied in four animals and triamcinolone
solution was applied in 12 animals.
Sequential Sampling From the Lateral
Semi-Circular Canal
Sequential sampling of perilymph makes it possible to quantify
drug concentration gradients along the perilymphatic spaces
(Mynatt et al., 2006; Salt et al., 2012). The LSCC was prepared for
perilymph sampling by first removing the mucosa and cleaning
the bone and with saline and cotton swabs. The bone overlying
the canal was thinned with a dental burr and a thin layer
of cyanoacrylate glue (Permabond 101; Permabond, Pottstown,
PA, United States) was applied. A covering of two-part silicone
adhesive (Kwik-Cast, World Precision Instruments, Sarasota, FL,
United States), was applied to this surface, built up at the edges to
form a hydrophobic cup. This allowed perilymph to be collected
free of contamination of drug solution in the rest of the bulla.
Sampling commenced by making a 30–40 µm fenestration
in the silicone-coated canal wall with a 30◦ House stapes pick
(N1705 80, Bausch and Lomb Inc.). The perilymph emerging
from the perforation accumulated on the hydrophobic surface
of the silicone where it was collected in hand-held, blunt
tipped capillary tubes (VWR 53432-706), marked to a nominal
volume of 1 µL. Twenty individual samples were collected from
each animal, each taking 1–2 min. The exact volume of each
sample was determined by measuring the sample length under
a calibrated dissecting microscope. The 20 samples were paired
consecutively and each pair added to 50 µL of 1:1 methanol:water
diluent, resulting in 10 diluted samples, each containing 2 µL
perilymph and 50 µL diluent. Samples were stored frozen at
−80◦C until analysis.
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Analysis of Samples
Samples were analyzed using high-pressure liquid
chromatography combined with mass spectrometry detection
(Wang et al., 2011). HPLC operators were blinded to the
experimental conditions and to the origin of the samples. The
LLOQ for triamcinolone was 0.2–1 ng/mL and the LLOQ for
triamcinolone-acetonide was 0.28 ng/mL. In experiments where
triamcinolone was applied to the ear only triamcinolone
was measured. In experiments where triamcinolone-
acetonide was applied, both triamcinolone-acetonide and
triamcinolone were measured.
Quantitative Simulation of Sequential
Sample Data
A computer program simulating the inner ear fluids (which
can be downloaded from)4 can be set to replicate all aspects
of the experiments performed in this study in great detail. For
intratympanic applications, calculations include known entry
sites from the middle ear into perilymph of the guinea pig,
including the RW, stapes and through the thin bone at the apex.
Drug distribution through the fluid and tissue spaces of the entire
inner ear is calculated based on defined diffusion coefficients
and elimination rates. Simulation of drug injections into the
lateral SCC and the sequential sampling procedure takes into
account the induced volume flows. In the perilymph sampling
procedure, the specific volumes and collection times for each of
the samples are replicated. Rates of elimination were adjusted to
best fit the calculated sample concentrations from the model to
the measured sample data, allowing the kinetic properties of the
drugs to be compared quantitatively.
RESULTS
Triamcinolone-Acetonide Kinetics
Triamcinolone-acetonide suspension was applied to the RW
niche for 60 min before perilymph was sampled. Figure 2
shows the perilymph levels measured when the triamcinolone-
acetonide suspension was applied as a liquid (green) or gel
(blue) formulation. Perilymph concentrations were found to
be lower than found in previous studies with a dexamethasone
suspension (red dashed line; from Salt et al., 2018). It is
important to note that these are results using dexamethasone
suspension, which differ considerably from the commonly used
solution of dexamethasone-phosphate. The average across all 40
samples for triamcinolone-acetonide was 0.71 ug/mL compared
to 2.16 ug/mL for dexamethasone. Although perilymph
triamcinolone-acetonide concentrations were lower than those
for dexamethasone by a factor of 3.1×, this is largely explained
by differences in the middle ear concentration of the two drugs.
Triamcinolone-acetonide has 3.6× lower aqueous solubility
(26.5 ug/mL) compared to dexamethasone (94.2 ug/mL), so
there will be a lower concentration driving entry into perilymph.
Although both triamcinolone and triamcinolone-acetonide were
4http://oto.wustl.edu/saltlab
FIGURE 2 | Perilymph triamcinolone-acetonide concentrations achieved 1 h
after application of triamcinolone-acetonide suspension to the RW niche of
guinea pigs. Perilymph was collected as 10 × 2 uL sequential samples from
the LSCC, each of which was analyzed independently. Early samples originate
from the vestibule, followed by SV and ST in sequence. In two experiments
the drug suspension was applied as a liquid (green curves) and in two
experiments in poloxamer gel (blue curves), with similar results. The group
mean (four experiments) is shown as a black dotted line. For comparison the
group mean results of similar experiments applying dexamethasone
suspension (Salt et al., 2018) are shown as the red dotted line.
measured in the samples, the vast majority of the drug was
present in perilymph as triamcinolone-acetonide. In 37 of the 40
samples triamcinolone concentration was unmeasurable, but in
three of the samples a low concentration of triamcinolone was
present, averaging just 1.4% of the total drug concentration.
In separate experiments the rate of triamcinolone-acetonide
elimination from perilymph was quantified by loading perilymph
by injection from a pipette sealed into the lateral SCC.
Figure 3A shows the measured perilymph concentrations from
four experiments, two sampled immediately after loading and
two measured at 2 h after loading. Concentrations shown
are the sum of triamcinolone-acetonide and triamcinolone in
each sample. These studies show that triamcinolone-acetonide
elimination occurred extremely rapidly, falling to 5–10% of
the applied concentration within 2 h. The declining curve for
perilymph seen with zero delay time was also consistent with
rapid elimination. It shows the injection rate was insufficient
to load the ear uniformly with drug, due to the high ongoing
elimination rate during injection. Simulations fitted to the
perilymph measurements provide the most quantitative way to
compare kinetics across drugs. Elimination rates that best-fitted
the measured data (dotted lines) were half times of 34 min in
SV and 12 min in ST. These are the most rapid rates of drug
elimination from perilymph we have ever measured. Figure 3B
(solid lines) shows the calculated perilymph distribution of
triamcinolone-acetonide at the three sampling times. Also shown
on the plot for comparison (dotted lines) is the calculated
distribution for dexamethasone at the same times, using a ST
elimination half-time of 46 min and a SV elimination half-time
of 91 min (Salt et al., 2018). Elimination of triamcinolone-
acetonide occurs far faster than that of dexamethasone. The
metabolism of triamcinolone-acetonide to triamcinolone was
also apparent in the data from canal injection experiments,
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FIGURE 3 | (A) Elimination measurement of triamcinolone-acetonide. Solid lines with symbols are individual experiments in which triamcinolone-acetonide
concentrations of perilymph samples obtained by sequential sampling were measured either immediately (zero delay; red curves, n = 2) or 2 h (green curves, n = 2)
after perilymph loading. Dotted lines show calculated sample concentrations derived by simulation with elimination half time 12 min for ST and 34 min for SV,
parameters which best fit the data set. (B) Solid lines show the calculated distribution of triamcinolone-acetonide along the perilymphatic space at zero (red), 1 h
(blue), and 2 h (green) delay after loading calculated using the same kinetic parameters. For comparison curves based on a best fit to dexamethasone sampling data
are shown dotted (ST elimination: 46 min; SV elimination 91 min; Salt et al., 2018). Triamcinolone-acetonide is lost more rapidly from perilymph than dexamethasone,
faster than any other substance measured to date.
with triamcinolone making up 10.5% of the total in zero delay
experiments and 63.3% of the total after 2 h. The accumulation of
triamcinolone proportion with time provided the first indication
that triamcinolone was better retained in perilymph than
triamcinolone-acetonide.
Triamcinolone Kinetics
A suspension of triamcinolone was applied to the RW niche
either in acute experiments with sampling 1 or 3 h after
application to the RW niche, or as recovery experiments
with sampling 1 or 3 days after intratympanic injection. The
measured perilymph concentrations are summarized in Figure 4.
A relatively uniform perilymph concentration over the time
period was observed. Even after 3 days, triamcinolone crystals
were visible in the RW niche and the perilymph concentration
was maintained. The average concentrations for each of the
groups (averaging all samples) were 1.52 µg/mL (n = 3; 1 h);
0.71 µg/mL (n = 3; 3 h); 0.72 (n = 4; 1 day); and 1.07 (n = 2,
3 days). Significance testing with two way ANOVA indicated that
perilymph levels at 1 h were significantly higher than at 3 h and
1 day (Bonferroni, P< 0.001). It is also notable that the perilymph
concentrations of triamcinolone were quite similar to those
observed above with triamcinolone-acetonide, and even more so
when normalized for middle ear concentration differences for the
two forms of triamcinolone.
The rate of elimination of triamcinolone from perilymph was
measured by loading perilymph by injection from a pipette sealed
into the LSCC. The results of six experiments in which perilymph
was sampled after zero delay (n = 1), 1 hr delay (n = 3); or
2 h delay (n = 2) are summarized in Figure 5. The data show
that triamcinolone is retained well in perilymph, with initial
vestibular samples at 70% of the applied drug concentration
after 2 h. Dotted lines show the best fit of the kinetic model
to the data set, with elimination half times of 278 min in SV
and 700 min in ST. In Figure 5B the calculated distribution
of triamcinolone along the perilymphatic spaces for the three
time periods (solid lines) is compared with the distribution of
dexamethasone (dotted lines). It is apparent that triamcinolone is
retained in perilymph much better than triamcinolone-acetonide
and dexamethasone, consistent with the more polar properties of
this form of the molecule.
Based on the kinetic parameters for entry into perilymph
from the middle ear and elimination from perilymph to the
vasculature derived in this study, we are able to project how the
two forms of triamcinolone might compare with the distribution
of dexamethasone in the human cochlea. In each case, the drug
can be applied as a suspension so the concentration in the middle
ear is assumed constant over the 24 h period calculated, with the
dissolved (free) concentration based on the aqueous solubility
of the compound. The calculated perilymph concentrations as
a function of distance along the cochlea and of time are shown
in Figure 6.
As triamcinolone-acetonide is lost very rapidly from
perilymph it will not spread far apically before being lost.
Dexamethasone distributes further along the cochlea but
does not reach apical regions in appreciable concentration. In
contrast triamcinolone is calculated to distribute throughout
the length of the human cochlea as a result of the lower rate of
elimination from perilymph.
DISCUSSION
The elimination of locally applied drugs from perilymph has
a major influence on effective local drug therapy of the inner
ear. If elimination occurs more rapidly than the drug diffuses
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FIGURE 4 | Perilymph triamcinolone concentrations measured 1 h (A), 3 h (B), 1 day (C), and 3 days (D) after application of triamcinolone suspension to the RW
niche of guinea pigs. Perilymph was collected as 10×2 µL sequential samples each of which was analyzed independently. Each curve shows the measured data
from a single animal. Animal numbers in each group were 3, 3, 4, and 2, respectively. For each group the mean is shown as a dotted line.
FIGURE 5 | (A) Elimination measurement of triamcinolone. Solid lines with symbols are the group means of the number of experiments indicated in which
triamcinolone concentrations of perilymph samples obtained by sequential sampling were measured either immediately (zero delay; red curve, n = 1), 1 h (blue curve,
n = 3), or 2 h (green curve, n = 2) after perilymph loading. Dotted lines show calculated sample concentrations derived by simulation with elimination half time
700 min for ST and 278 min for SV; parameters which best fit this data set. (B) Solid lines show the distribution of triamcinolone along the perilymphatic space at
zero, 1 and 2 h delay after loading calculated using the same parameters. For comparison, curves calculated based on a best fit to dexamethasone sampling data
are shown dotted (ST elimination: 46 min; SV elimination 91 min; Salt et al., 2018).
along the scala, this may limit the distribution of the drug along
the cochlea. The influence of elimination also depends on the
cochlear dimensions of the species under study. For a given drug,
concentration gradients along the ear as a result of elimination
will be substantially smaller in short cochleas, such as those of
mice, and greater in longer cochleas, such as those of humans.
Measurement of elimination from perilymph was performed
here by loading the fluid and tissue spaces of the inner ear with
drug and then following the subsequent decline of drug with time
by taking fluid samples at varying delay times after loading. This
method overcomes difficulties with other application methods
where drug gradients in the ear may exist. If drug gradients
exist, decline of drug concentration due to distribution into
regions of lower concentration cannot be differentiated from the
decline due to elimination. Triamcinolone-acetonide was shown
to be rapidly eliminated from perilymph while triamcinolone
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FIGURE 6 | Simulation of intratympanic applications of triamcinolone-acetonide suspension (A), dexamethasone suspension (B), and triamcinolone suspension (C)
to the human ear. Entry and elimination kinetics are based on perilymph measurements in guinea pigs. ST elimination half-times were 12, 44, and 700 min for
triamcinolone-acetonide, dexamethasone, and triamcinolone, respectively. Triamcinolone-acetonide and dexamethasone only distribute apically to a limited degree
before reaching a steady state, unlike triamcinolone which reaches the cochlear apex.
had completely different characteristics and was retained well.
Elimination of dexamethasone occurred at an intermediate rate.
The measured elimination characteristics are consistent with the
polar properties of the three molecules influencing passage across
biological lipid membrane boundaries. In the case of elimination
measurements, the molecular properties likely influence their
ability to pass through cell membranes of the capillary endothelial
cells (Salt and Hirose, 2018).
An interesting observation from this study is that while
elimination differed markedly between triamcinolone-acetonide
(fast) and triamcinolone (slow), the perilymph levels measured
with RW niche applications were similar for both drugs.
Simulations (not shown) indicate that perilymph concentration
of drug depends on the rate of entry from the middle ear,
balanced against the losses from perilymph due to elimination
to blood and from interactions with cerebrospinal fluid.
A similar perilymph level can result from fast entry with
fast elimination (as in the case of triamcinolone-acetonide) or
from slower entry with a slower rate of elimination (as in
the case of triamcinolone). This raises an intriguing idea as
it suggests that measured perilymph concentrations resulting
from intratympanic applications cannot be easily interpreted
in terms of the underlying perilymph pharmacokinetics. The
similar perilymph levels observed here with triamcinolone
and triamcinolone-acetonide gave no indication that the
underlying kinetics in perilymph were completely different.
In order to understand the perilymph kinetics additional
measurements, such as measurement of elimination as performed
here is required.
Our pharmacokinetic measurements suggest that
triamcinolone should be considered as a potential therapy
for auditory disorders where steroid therapy is indicated.
Specifically, triamcinolone has pharmacokinetic properties that
are predicted to allow it to reach apical cochlear regions of
the human ear in higher concentration, potentially allowing
all frequency regions to be treated. The choice of steroid for
use in the clinic is, however, complex and based on many
factors other than pharmacokinetic studies in animals. For
instance, relative potencies at the target receptors are critical.
Triamcinolone has been reported to have 660× lower potency
than dexamethasone, while triamcinolone-acetonide may have
2–6× higher potency than dexamethasone at the glucocorticoid
receptor (Mayer et al., 1974; Pratt et al., 1975; Yeakley et al., 1980;
Grossmann et al., 2004; Nehmé et al., 2009). Potency estimates
vary with many factors, however, including species, tissue and
application duration (Giannopoulos and Keichline, 1981; Nehmé
et al., 2009). Relative steroid potency remains unmeasured
for tissues of the human inner ear. The relative affinity of
mineralocorticoid receptors to the different steroids is also
unknown. Another major factor concerns the difference between
the concentrations of steroid in the tissues compared to those
in perilymph and the factors contributing to tissue absorption.
Although dexamethasone time courses have been compared in
tissues and plasma with systemic dosing (Cherlet et al., 2005;
Li et al., 2017) and in vitreous humor and retina tissues for
the eye with local delivery (Chang-Lin et al., 2011), neither of
these systems exhibit concentration gradients comparable to
those seen in the ear. The cochlear tissue concentrations of
steroid resulting from different perilymph distributions therefore
remain unknown. It is possible that for some therapies of
the ear, such as the treatment of Meniere’s disease, the spatial
distribution of drug may not be a limiting factor and treatment of
vestibular and basal cochlear tissue may be sufficient. In animals,
triamcinolone-acetonide therapy.
So in some cases, there may be limited benefit to a more
apical distribution of drug along the cochlea. It therefore becomes
important to evaluate how patients with auditory disorders
respond to triamcinolone therapy. Unfortunately, human pilot
studies with triamcinolone have been hampered by the lack
of an available formulation approved for intravenous use, as
exists for triamcinolone-acetonide. As triamcinolone-acetonide
has higher potency for systemic delivery it has replaced the use
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of triamcinolone, so comparable formulations of triamcinolone
are no longer available. Nevertheless, for the treatment of
auditory disorders, a drug which can provide apical regions
with substantially higher concentration would seem desirable
and potentially allow all frequency regions of the human
ear to be treated.
The three drugs compared here were all delivered to the
middle ear as crystalline suspensions, which dissolve slowly
over a period of weeks. Unlike solutions, where drug is lost
rapidly from the middle ear, suspensions provide a depot effect,
increasing the duration of the drug time course in perilymph.
Such a “depot,” influence has previously been reported for both
triamcinolone-acetonide (Ye et al., 2007; Honeder et al., 2014)
and for dexamethasone (Wang et al., 2009, 2011).
Our studies show that the requirements for an effective
steroid for inner ear therapy are very different from those
for intravenous or oral therapies. With local therapy the ease
of passage through membranous boundaries, such as the RW
membrane and blood-perilymph barrier, influence the spatial
distribution of drug. The physical properties of the molecule
that determine membrane permeability (such as lipophilicity
and polarity) therefore play an important role in the cochlear
distribution of drug. With systemic delivery, the molecular form
is of lesser importance if the drug is metabolized to an active
form in organs such as the liver. We have previously shown
that the molecular properties of dexamethasone-phosphate
make it quite unsuitable for local therapy of the ear (Salt
et al., 2018). The present study shows that triamcinolone-
acetonide, a more potent form of triamcinolone in widespread
clinical use, also does not have appropriate kinetic properties
for local treatment of the ear. In contrast, the more polar
triamcinolone appears better suited. We conclude that the
properties that make a drug suitable for local use in the ear are
completely different from those that make the drug suitable for
intravenous or oral use.
A key factor to improve drug distribution along the
length of the ear is to reduce the rate of elimination. The
triamcinolone molecule is almost identical to dexamethasone,
differing by one non-polar CH3 group in dexamethasone which
is replaced by a polar OH group in triamcinolone. As can
be seen in our measurements, this modest increase in polar
properties markedly increases retention in perilymph, thus
predicting the drug to be distributed more evenly along the
ear. One possible confounding factor could have been that the
reduced passage through membranous boundaries would limit
entry from the middle ear. The perilymphatic measurements
with local applications showed that any reduction in entry
from the middle ear is largely offset by reduced rate of
elimination, so that the measured perilymph concentration of
triamcinolone was similar to that of triamcinolone-acetonide
(Figures 2, 4).
CONCLUSION
In conclusion, the studies described herein suggest that
administration to the middle ear of a triamcinolone
suspension yields an attractive pharmacokinetic profile in the
perilymph. These measurements show that triamcinolone could
provide an additional treatment option for local therapy of
auditory disorders.
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